PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 65 filers reported holding PROTAGONIST THERAPEUTICS INC in Q1 2019. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $438,000 | -78.9% | 62,166 | -64.0% | 0.01% | -76.0% |
| Q3 2019 | $2,074,000 | -20.6% | 172,706 | -20.0% | 0.05% | -10.7% |
| Q2 2019 | $2,613,000 | +46.5% | 215,756 | +52.0% | 0.06% | +43.6% |
| Q1 2019 | $1,784,000 | +88.4% | 141,945 | +0.9% | 0.04% | +56.0% |
| Q4 2018 | $947,000 | -50.3% | 140,714 | -25.0% | 0.02% | -37.5% |
| Q3 2018 | $1,904,000 | +70.5% | 187,653 | +14.7% | 0.04% | +90.5% |
| Q2 2018 | $1,117,000 | -21.5% | 163,667 | -1.2% | 0.02% | -30.0% |
| Q1 2018 | $1,423,000 | +109.3% | 165,606 | +397.3% | 0.03% | +100.0% |
| Q4 2017 | $680,000 | – | 33,302 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 2,449,183 | $43,400,000 | 3.81% |
| BVF INC/IL | 3,901,759 | $69,139,000 | 2.70% |
| COMMODORE CAPITAL LP | 498,079 | $8,826,000 | 2.33% |
| Altium Capital Management LP | 346,000 | $6,131,000 | 1.61% |
| Twin Lakes Capital Management, LLC | 139,287 | $2,468,000 | 1.45% |
| Opaleye Management Inc. | 330,222 | $5,852,000 | 1.09% |
| EcoR1 Capital, LLC | 1,443,800 | $25,584,000 | 0.89% |
| OBERMEYER WOOD INVESTMENT COUNSEL, LLLP | 776,689 | $13,763,000 | 0.76% |
| JABODON PT CO | 90,656 | $1,606,000 | 0.66% |
| Artal Group S.A. | 1,500,000 | $26,580,000 | 0.60% |